The bioavailability of oral fludarabine phosphate is unaffected by food.

[1]  T. Lister,et al.  Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Gobbi,et al.  First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease , 1998, European journal of haematology.

[3]  F. Bosch,et al.  Treatment of B‐cell chronic lymphocytic leukaemia: current status and future perspectives , 1997, Journal of internal medicine. Supplement.

[4]  B. Cheson,et al.  Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Estey,et al.  Clinical experience with fludarabine in hemato-oncology. , 1996, Hematology and cell therapy.

[6]  C. Falkson.  Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma. , 1996, American journal of clinical oncology.

[7]  W. Hiddemann,et al.  Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia , 1996, The Lancet.

[8]  F. Bosch,et al.  Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. , 1996, Leukemia & lymphoma.

[9]  A. Polliack,et al.  Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma--the Jerusalem experience. , 1994, Leukemia & lymphoma.

[10]  L. Canepa,et al.  Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. , 1994, Haematologica.

[11]  S. Noga,et al.  Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. , 1993 .

[12]  E. Estey,et al.  Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. , 1993, Seminars in oncology.

[13]  E. Estey,et al.  Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. , 1993, Blood.

[14]  E. Estey,et al.  Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. , 1993, Blood.

[15]  M. Oken,et al.  Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Bauman,et al.  A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. , 1991, Clinica chimica acta; international journal of clinical chemistry.